MetaCap

Armata Pharmaceuticals (ARMP) vs Innate Pharma S.A. (IPHA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Innate Pharma S.A. (IPHA) has outperformed Armata Pharmaceuticals (ARMP) over the past year, losing 52.6% versus a loss of 56.9%. Over five years, ARMP leads with a -42.0% price change compared with -82.0% for IPHA. Armata Pharmaceuticals is the larger company by market cap ($112.7 million vs $96.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARMP-56.90%IPHA-52.56%
+119%+24%-71%
Nov 21, 20251 yearNov 20, 2026
ARMP-22.70%IPHA-82.77%
+245%+73%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARMP versus IPHA key metrics
MetricARMPIPHA
Share price$3.03$0.8634
Market cap$112.69M$96.44M
1-day change+1.68%-8.14%
YTD return-51.75%-50.66%
1-year return-56.90%-52.56%
5-year return-41.95%-82.01%
EPS (TTM)$-4.17$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-173.80M—
52-week high$14.98$2.71
52-week low$2.40$0.829
Distance from 52-week high-79.77%-68.14%
Analyst consensusnonebuy
Avg. price target upside+477.56%+826.57%
Average volume182.52K42.76K
Shares outstanding37.19M111.70M
Employees61120
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Armata Pharmaceuticals

ARMP stock →

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees

About Innate Pharma S.A.

IPHA stock →

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees

ARMP vs IPHA FAQ

Which is bigger, Armata Pharmaceuticals or Innate Pharma S.A.?

Armata Pharmaceuticals (ARMP) is larger, with a market capitalization of $112.69M compared with $96.44M for Innate Pharma S.A. (IPHA).

Which stock has performed better over the past year, ARMP or IPHA?

IPHA returned -52.56% over the past 12 months, compared with -56.90% for ARMP (price return, excluding dividends). Past performance does not predict future results.

Are Armata Pharmaceuticals and Innate Pharma S.A. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons